Clinical Trial The lancet. HIV. 2017 Dec;4(12):e536-e546. doi: 10.1016/S2352-3018(17)30095-4 Q113.02025
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study
一项在先前未接受过治疗的感染HIV-1女性中比较多替拉韦、阿巴卡韦和拉米夫定与阿扎那韦/利托那韦增强剂联合恩曲他滨和富马酸替诺福韦二吡呋酯疗效的随机开放性非劣效性3b期研究（ARIA）：第48周结果 翻译改进
Catherine Orrell 1, Debbie P Hagins 2, Elena Belonosova 3, Norma Porteiro 4, Sharon Walmsley 5, Vicenç Falcó 6, Choy Y Man 7, Alicia Aylott 8, Ann M Buchanan 7, Brian Wynne 9, Cindy Vavro 7, Michael Aboud 10, Kimberly Y Smith 7; ARIA study team
作者单位 +展开
作者单位
DOI: 10.1016/S2352-3018(17)30095-4 PMID: 28729158
摘要 Ai翻译
相关内容
-
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy
埃拉韦/柯比司他/恩曲他滨/富马酸替诺福韦二吡美.drive和阿巴卡韦/拉米夫drive+多替克韦用于初次治疗的疗效及安全性的非直接对比研究
Josep M Llibre et al.
PloS one. 2016 May 19;11(5):e0155406.
-
Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s
阿巴卡韦-拉米夫定或恩曲他滨-替诺福韦联合阿扎那韦-利托那韦或依非韦伦治疗患者的外周及中央型脂肪变化：ACTG研究A5224s
Grace A McComsey et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Jul 15;53(2):185-96.
-
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine
奥比塔斯维-帕利他韦-利托那韦联合达萨布韦与治疗艾滋病的抗逆转录病毒药物多替拉韦或阿巴卡韦和拉米夫定之间相互作用的研究
Amit Khatri et al.
Antimicrobial agents and chemotherapy. 2016 Sep 23;60(10):6244-51.
-
Bioequivalence of a dolutegravir, abacavir, and lamivudine fixed-dose combination tablet and the effect of food
多替拉韦、阿巴卡韦和拉米夫定复方制剂的生物等效性及其受食物影响的情况
Stephen Weller et al.
Journal of acquired immune deficiency syndromes (1999). 2014 Aug 1;66(4):393-8.
-
Dolutegravir, abacavir and lamivudine as HIV therapy
多替拉韦、阿巴卡韦和拉米夫定作为治疗艾滋病的药物
Jose Vicente Fernandez-Montero et al.
Expert opinion on pharmacotherapy. 2014 May;15(7):1051-7.
-
Evaluation of Subclinical Left Ventricular Dysfunction in HIV Patients Receiving Abacavir, Dolutegravir, and Lamivudine Therapy with Novel Tissue Doppler Imaging Techniques
接受阿巴卡韦、多立韦瑞和拉米夫定治疗的HIV患者亚临床左心室功能障碍的新组织多普勒成像技术评估
Dogac Oksen et al.
Journal of clinical medicine. 2025 Feb 25;14(5):1534.
-
Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters
多替拉韦搭配阿巴卡韦/拉米夫定对青少年有效，但疗效和体重有关
Ferran Bossacoma Busquets et al.
The Journal of antimicrobial chemotherapy. 2017 Oct 1;72(10):2958-2960.
-
Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells
替诺福韦、拉米夫定、阿巴卡韦和叠氨基脱氧胸苷在原代人类细胞中的相互作用
Omar Janneh
Pharmaceutics. 2011 Jun 22;3(2):326-37.
引文链接
复制
已复制！
推荐内容
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study